Consistency of Bone Turnover Marker and Calcium Responses to Parathyroid Hormone (1-84) Therapy in Postmenopausal Osteoporosis

Journal of Clinical Densitometry

Volumn 14, Issue 1, 2011, Pages 68-73

  Schafer, Anne L ^a   Palermo, Lisa ^a   Bauer, Douglas C ^a   Bilezikian, John P ^b   Sellmeyer, Deborah E ^c   Black, Dennis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Howard Hughes Medical Institute   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone turnover markers; Bone specific alkaline phosphatase; C terminal telopeptide (CTX); Calcium; Parathyroid hormone

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE; PROCOLLAGEN; TUMS; VITAMIN D;

AGED; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

AGED; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; CALCIUM CARBONATE; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PEPTIDES;

EID: 79551489952     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2010.09.001     Document Type: Article

References (16)

1. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
2. Greenspan S.L., Bone H.G., Ettinger M.P., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007, 146:326-339.
3. Bauer D.C., Garnero P., Bilezikian J.P., et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2006, 91:1370-1375.
4. Chen P., Satterwhite J.H., Licata A.A., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20:962-970.
5. Lane N.E., Sanchez S., Genant H.K., et al. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 2000, 11:434-442.
6. Sellmeyer D.E., Black D.M., Palermo L., et al. Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis. Osteoporos Int 2007, 18:973-979.
7. Eastell R., Robins S.P., Colwell T., et al. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int 1993, 3:255-260.
8. Glover S.J., Eastell R., McCloskey E.V., et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009, 45:1053-1058.
9. Orwoll E.S., Scheele W.H., Paul S., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17.
10. Antoniucci D.M., Sellmeyer D.E., Bilezikian J.P., et al. Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis. J Clin Endocrinol Metab 2007, 92:942-947.
11. Miller P.D., Bilezikian J.P., Diaz-Curiel M., et al. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 2007, 92:3535-3541.
12. Gold D.T., Pantos B.S., Masica D.N., et al. Initial experience with teriparatide in the United States. Curr Med Res Opin 2006, 22:703-708.
13. Black D.M., Greenspan S.L., Ensrud K.E., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
14. Glover A.J., Gall M., Schoenborn-Kellenberger O., et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 2009, 24:389-397.
15. Hodsman A.B., Hanley D.A., Ettinger M.P., et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:5212-5220.
16. Lindsay R., Nieves J., Formica C., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.